Literature DB >> 26697842

A DDB2 mutant protein unable to interact with PCNA promotes cell cycle progression of human transformed embryonic kidney cells.

Paola Perucca1, Sabrina Sommatis1, Roberto Mocchi1, Ennio Prosperi2, Lucia Anna Stivala1, Ornella Cazzalini1.   

Abstract

DNA damage binding protein 2 (DDB2) is a protein involved in the early step of DNA damage recognition of the nucleotide excision repair (NER) process. Recently, it has been suggested that DDB2 may play a role in DNA replication, based on its ability to promote cell proliferation. We have previously shown that DDB2 binds PCNA during NER, but also in the absence of DNA damage; however, whether and how this interaction influences cell proliferation is not known. In this study, we have addressed this question by using HEK293 cell clones stably expressing DDB2(Wt) protein, or a mutant form (DDB2(Mut)) unable to interact with PCNA. We report that overexpression of the DDB2(Mut) protein provides a proliferative advantage over the wild type form, by influencing cell cycle progression. In particular, an increase in the number of S-phase cells, together with a reduction in p21(CDKN1A) protein level, and a shorter cell cycle length, has been observed in the DDB2(Mut) cells. These results suggest that DDB2 influences cell cycle progression thanks to its interaction with PCNA.

Entities:  

Keywords:  DDB2; DNA replication, PCNA; cell cycle; tumor growth

Mesh:

Substances:

Year:  2015        PMID: 26697842      PMCID: PMC4825770          DOI: 10.1080/15384101.2015.1120921

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  33 in total

1.  p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies.

Authors:  Tanya Stoyanova; Nilotpal Roy; Shaumick Bhattacharjee; Dragana Kopanja; Ted Valli; Srilata Bagchi; Pradip Raychaudhuri
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 2.  The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs.

Authors:  L A Stivala; O Cazzalini; E Prosperi
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

3.  DDB2 association with PCNA is required for its degradation after UV-induced DNA damage.

Authors:  Ornella Cazzalini; Paola Perucca; Roberto Mocchi; Sabrina Sommatis; Ennio Prosperi; Lucia Anna Stivala
Journal:  Cell Cycle       Date:  2013-11-04       Impact factor: 4.534

4.  CRL4(CDT2) targets CHK1 for PCNA-independent destruction.

Authors:  Jiwon Huh; Helen Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2012-10-29       Impact factor: 4.272

5.  Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB) dimerization and its roles in chromatinized DNA repair.

Authors:  Joanne I Yeh; Arthur S Levine; Shoucheng Du; Unmesh Chinte; Harshad Ghodke; Hong Wang; Haibin Shi; Ching L Hsieh; James F Conway; Bennett Van Houten; Vesna Rapić-Otrin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-20       Impact factor: 11.205

6.  Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27.

Authors:  Yiyi Yan; Xiaoshan Zhang; Randy J Legerski
Journal:  Cell Cycle       Date:  2011-12-01       Impact factor: 4.534

7.  p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells.

Authors:  N-N Kreis; M Sanhaji; M A Rieger; F Louwen; J Yuan
Journal:  Oncogene       Date:  2013-12-09       Impact factor: 9.867

8.  DDB2 suppresses epithelial-to-mesenchymal transition in colon cancer.

Authors:  Nilotpal Roy; Prashant V Bommi; Uppoor G Bhat; Shaumick Bhattacharjee; Indira Elangovan; Jing Li; Krushna C Patra; Dragana Kopanja; Adam Blunier; Richard Benya; Srilata Bagchi; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

9.  DDB2: a novel regulator of NF-κB and breast tumor invasion.

Authors:  Marie Ennen; Rémi Klotz; Nadège Touche; Sophie Pinel; Claire Barbieux; Vanessa Besancenot; Emilie Brunner; Denise Thiebaut; Alain C Jung; Sonia Ledrappier; Lionel Domenjoud; Joseph Abecassis; François Plénat; Stéphanie Grandemange; Philippe Becuwe
Journal:  Cancer Res       Date:  2013-06-17       Impact factor: 12.701

10.  Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.

Authors:  C Barckhausen; W P Roos; S C Naumann; B Kaina
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

View more
  2 in total

Review 1.  Emerging Roles of DDB2 in Cancer.

Authors:  Pauline Gilson; Guillaume Drouot; Andréa Witz; Jean-Louis Merlin; Philippe Becuwe; Alexandre Harlé
Journal:  Int J Mol Sci       Date:  2019-10-18       Impact factor: 5.923

2.  Exploring new potential role of DDB2 by host cell reactivation assay in human tumorigenic cells.

Authors:  Elisabetta Bassi; Paola Perucca; Isabella Guardamagna; Ennio Prosperi; Lucia A Stivala; Ornella Cazzalini
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.